Related Experiment Video
Updated: Sep 21, 2025
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.3K
Rational Second-Generation Antiandrogen Use in Prostate Cancer.
Jacob J Orme1, Lance C Pagliaro1, J Fernando Quevedo1
1Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
The Oncologist
|May 31, 2022
Summary
Second-generation antiandrogens offer new prostate cancer treatment options. Optimal sequencing with chemotherapy and other therapies can improve efficacy and tolerability in advanced prostate cancer.
Area of Science:
- Oncology
- Pharmacology
Background:
- Second-generation antiandrogens are increasingly approved for prostate cancer subsets.
- Effective treatment strategies are needed for advanced prostate cancer.
Purpose of the Study:
- To review second-generation antiandrogen trials and FDA approvals.
- To outline a rational sequencing approach for these agents in advanced prostate cancer.
Main Methods:
- Systematic review of published phase II-III randomized controlled trials.
- Inclusion of trials and retrospective studies on sequencing and combinations.
- Tabular and graphical representation of evidence.
Main Results:
- Evidence supports abiraterone before chemotherapy in metastatic castration-resistant prostate cancer.
- Chemotherapy is recommended after second-generation antiandrogen failure.
- Post-chemotherapy enzalutamide may benefit select patients.
Conclusions:
- A rational sequencing of second-generation antiandrogens with other treatments is feasible.
- Optimized sequencing can maximize agent efficacy and tolerability in advanced prostate cancer.
Related Concept Videos
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.0K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.0K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
665
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
665
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
261
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
261
01:25Antihypertensive Drugs: Direct Renin Inhibitors
852
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
852
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
528
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
528